118 results about "Hemorrhagic Fevers" patented technology

The present invention provides oligonucleotide primers, compositions, and kits containing the same for rapid identification of viruses that cause viral hemorrhagic fevers by amplification of a segment of viral nucleic acid followed by molecular mass analysis.

The invention concerns agents for the treatment of acute and chronic infections with human and animal pathogenic viruses which assemble along the cell membrane and are released through budding on the surface of the cell. Hereunto count especially causative agents of infectious diseases such as AIDS, hepatitis, hemorrhagic fever, SARS, smallpox, measles, polio or the flu. The subjects of the invention are agents that contain inhibitors of the protein folding as active components. Hereunto count inhibitors of cellular folding enzymes (the enzymatic chaperones) as well as substances that disturb the folding of proteins through chemical chaperones. The following substance classes and their derivates belong thereunto: Geldanamycin, Deoxyspergualin, 4-PBA or Herbimycin A. Due to these agents the highly organised processes of the assembly and the proteolytical maturation of virus structure proteins is disturbed. As a result the release and production of infectious decendent viruses is prevented.

The invention discloses a fluorescence quantitative polymerase chain reaction (PCR) new method for detecting multiple viruses of yellow fever, dengue fever and epidemicencephalitis B and multiple virus detection PCR system consisting of primers, probes, a Premix Ex Taq reaction solution and a sterilized Tris buffer. With good singularity and high sensitivity, three pairs of primers and probes are very suitable for simultaneously detecting viruses of yellow fever, dengue fever and epidemicencephalitis B. And there is no cross reaction between the primers and probes and several other entomophily hemorrhagic fever viruses, such as Marburg virus and Rift Valley fever virus.

The invention features compositions, methods, and kits useful for the treatment of filovirus-mediated diseases, e.g., hemorrhagic fever caused by Ebola virus, in an animal.

Recombinant VSV viral particles and the use thereof as vaccines for immunization are described.

The invention features compositions, methods, and kits useful for the treatment of filovirus-mediated diseases, e.g., hemorrhagic fever caused by Ebola virus, in an animal.

The invention relates to the technical field of biological detection, in particular to a detection method of hemorrhagic fever with renal syndrome IgM (immunoglobulin M) antibodies and a reagent kit. The detection method comprises the steps that hemorrhagic fever with renal syndrome antigens are fixed on a membrane; to-be-detected serum is added; the hemorrhagic fever with renal syndrome IgM antibodies in the to-be-detected serum are combined with the antigens fixed on the membrane; gold labeled operating fluid containing mouse anti-human IgM monoclonal antibodies is added; the mouse anti-human IgM monoclonal antibodies are combinec with the hemorrhagic fever with renal syndrome IgM antibodies in the to-be-detected serum; a red color is shown; scrubbing liquid is added finally; and the redundant gold labeled operating fluid and other impurities are washed out. The reagent kit has the characteristics of longer quality guarantee period, less cross reaction, better color rendering performance and the like.

The present invention provides methods of treating hemorrhagic fevers where selective inhibitors of fVIIa / TF are used as a treatment for hemorrhagic fevers and have therapeutic effects which include ameliorating and / or preventing coagulopathy and inflammatory responses. These inhibitors include certain proteins which are part of a family termed Nematode-Extracted Anticoagulant Proteins (“NAPs”). Other inhibitors include Tissue Factor Pathway Inhibitor (“TFPI”) and TFPI analogs.

The invention discloses a neutralizing monoclonal antibody 3D8 identified HTNV-GP specific B cell epitope and key amino acid residue sequence of the epitope for treating hemorrhagic fever with renal syndrome (HFRS) caused by hantaan virus (HTNV) infection. The B cell epitope has an amino acid sequence of 882GFLCPEFPGSFRKKC896. The epitope peptide can be applied to study of mechanism of 3D8 neutralizing monoclonal antibody in treatment of HFRS, or preparation of drug for treating HFRS and preparation of novel vaccine strain aiming at hantaan virus 76-118, or development of novel diagnostic kitfor hantaan virus 76-118 as a target protein. The invention has good prospects of development and application in the field of HFRS specific immunotherapy.

The invention discloses application of a medicine in resisting Hantaan viruses, namely arbidol. The arbidol has obvious effect of inhibiting the Hantaan viruses in vitro, and the antivirus effect of drug administration before the viruses enter a cell is stronger than that of the drug administration after the viruses enter the cell. The concrete embodiment comprises the following: the drug administration is performed before and after the infection, the positive rate of virus-infected cells and the fluorescence intensity are reduced along with the concentration increase, and the medicine has dosage effect; and the medicine can obviously reduce the positive rate of virus infection, and the mRNA expression of the viruses is reduced. The arbidol has protection and treatment effect on the infection of the Hantaan viruses on a suckling mouse, and the protection effect is stronger than the treatment effect. The drug administration is performed within 24h before the infection; and with the increase of the dosage of the medicine, the death rate of the mouse is reduced, and the average survival days are extended. The drug administration within 24h after the infection can not improve the survival rate of an animal, but can extend the average survival days of the animal. The arbidol has the effect of inhibiting the Hantaan viruses in a body of the animal. The drug administration within 24h before the infection can lighten the pathologic change of tissues (lung, kidney, and brain), and has treatment effect on HFRS. The medicine has prevention effect and also has treatment effect on patients with the hemorrhagic fever with renal syndrome (HFRS) caused by the Hantaan viruses, and no toxic side effect is found.

The invention involves nephrotic syndrome hemorrhagic fever Vero cells purified bivalent vaccine and its industrialized preparation methods. The nephrotic syndrome hemorrhagic fever Vero cells bivalent purified vaccine in the inventioncontains effective doses of nephrotic syndrome hemorrhagic fever deactive virus type I, type II and vaccine adjuvants, the type I and type II virus are from PS-6 (C-3) strains, CCTCC-V200503 and L99(C-2) strains, CCTCC-V200504 respectively. The preparation method of the invention includes: 1. Preparating the vaccine stock solution nephrotic syndrome hemorrhagic fever virus PS-6(C-3), CCTCC-V200503 and L99(C-2),CCTCC-V200504, inactivating virus with formaldehyde; 2. combining the deactive vaccine stock solution of PS-6(C-3), CCTCC-V200503 and L99(C-2),CCTCC-V200504 and purifying, the process contains centrifugal separation, hyperfiltration, concentration, zinc acetate deposition and column chromatography; 3. adding adjuvant into the purified vaccine stock solution and getting the purified bivalent vaccine. The nephrotic syndrome hemorrhagic fever Vero cells purified bivalent vaccine in the invention is suitable for the prevention of nephrotic syndrome hemorrhagic fever mainly based on all type I and type II.

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever and Crimean-Congo hemorrhagic fever).

The invention aims to provide a TeiGuanYin organic tea leaf containing nano-selenium and a method for picking the same. The TeiGuanYin organic tea leaf containing nano-selenium contains 40 to 65 mg of the nano-selenium per 100g, the nano-selenium is between 50 and 200 nm and the balance being dietary fibers, carbohydrates, proteins, microelements and vitamins A, A1, B1, B2, B5, E, renieratene and elements such as manganese, magnesium, phosphorus, zinc, iron, copper, sodium, calcium, potassium, thereby conforming to the standard of organic tea. The selenium is a necessary element of the human body and has functions of eliminating free radicals, preventing cancer, caring beauty and delaying aging, losing weight, resisting radiation, regulating immunity and treating the Keshan disease and so on, and is a nutritional anti-cancer agent recognized in the medical field. The frequent drinking of the nano-selenium TeiGuanYin organic tea has better effect to prevent various diseases such as hepatitis, arthritis, cataract and cardiovascular disease hemorrhagic fever and contributes to health and longevity for the middle-aged and the old.